Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • Regeneron held its annual shareholder meeting on June 12, 2026.
  • Shareholders selected five Class II director nominees to serve until the 2027 annual meeting.
  • PwC’s appointment as independent registered public accounting firm for the year ending Dec. 31, 2026 was ratified.
  • An advisory resolution backing executive pay was adopted; it does not itself implement any pay actions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-075127), on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.